Cytek Biosciences
CTKB
101 hedge funds and large institutions have $658M invested in Cytek Biosciences in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 18 reducing their positions, and 25 closing their positions.
4,083% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $36K
183% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 18
6.2% more ownership
Funds ownership: 50.59% → 56.78% (+6.2%)
4% more capital invested
Capital invested by funds: $630M → $658M (+$28.3M)
1% less funds holding
Funds holding: 102 → 101 (-1)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$61.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.5M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$19.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$11.9M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$10.2M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.72M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$9.39M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.61M |
CTKB Hedge Fund Activity: Q2 2023 in Review
101 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q2 2023, worth a combined $658M — up 4.5% from $630M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CTKB and 24 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 51 added.
The largest buyer was BlackRock, adding an estimated $61.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $11.9M sold.
- 101 institutional investors held Cytek Biosciences (CTKB) as of Q2 2023, down from 102 in Q1 2023.
- Funds reported $658M of Cytek Biosciences stock for Q2 2023, up 4.5% quarter-over-quarter.
- 24 funds opened new Cytek Biosciences positions in Q2 2023 and 25 closed out, a net change of -1 holder.
- The largest Cytek Biosciences buyer in Q2 2023 was BlackRock, an estimated $61.4M added.
- The largest Cytek Biosciences seller in Q2 2023 was Perceptive Advisors, an estimated $11.9M sold.
Based on aggregated 13F filings for Q2 2023.